Takeda et al. identified a ROCK-survivin anti-apoptotic axis in pancreatic cancer stem cells and that inhibiting ROCK resulted in decreased survivin expression, leading to the sensitization of cells to gemcitabine[20]. This evidence concerns the gene BIRC5 and familial pancreatic carcinoma.